Sysmex Corp
TSE:6869
Sysmex Corp's latest stock split occurred on Mar 28, 2024
The company executed a 3-for-1 stock split, meaning that for every share held, investors received 3 new shares.
Before the split, Sysmex Corp traded at 8237 per share. Afterward, the share price was about 2673.1052.
The adjusted shares began trading on Mar 28, 2024. This was Sysmex Corp's 4th stock split, following the previous one in Mar 27, 2014.
BGLC
ATORX
TGL
Sysmex Corp
Glance View
In the bustling world of healthcare diagnostics, Sysmex Corporation stands as a beacon of innovation and precision. Originating from the vibrant city of Kobe, Japan, the company has mastered the art of transforming complex scientific processes into streamlined solutions. With roots tracing back to the 1960s, Sysmex emerged as a pioneer in the field of hematology, developing technological marvels that analyze blood components with remarkable accuracy. This precision is not merely an academic pursuit; it translates into actionable insights for medical professionals, empowering them to diagnose and monitor conditions ranging from anemia to leukemia with a high degree of reliability. As the lifeblood of medical laboratories worldwide, Sysmex's automated analyzers and testing systems are indispensable tools in pathologies, enabling swift and accurate patient care. Sysmex's business model is a symphony of product innovation and service excellence. The company thrives by blending advanced technologies with an ever-expanding portfolio of diagnostic instruments and reagents, ensuring that their systems remain both state-of-the-art and user-friendly. Revenue generation for Sysmex is a harmonious balance between instrument sales and the recurring income stream from consumables and after-sales service contracts. This dual approach not only secures initial capital from equipment sales but also ensures sustained engagement with their clients. By investing heavily in research and development, Sysmex continuously pushes the envelope in medical diagnostics, tapping into emerging fields like oncology, hemostasis, and urinalysis. In doing so, it fortifies its position as a global leader, committed to advancing healthcare outcomes through technological innovation and customer-centric practices.
You don't have any saved screeners yet